Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (09.03.2026)
HOCH Abgang Schlüsselpersonen (09.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 21.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Common Stock outstanding on January 21, 2026. Item 5.02. Departure of Directors or Certain Officers; Election of Direc |
| 21.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | he Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 08.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | he Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 27.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | he Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 16.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02. Resignation of Chief Financial Officer, Principal Financial Officer and Princi |
| 03.05.2024 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | the Exchange Act. ☐ Item 4.02. Non-Reliance on Previously Issued Financial Statements and Completed Interim R |
| 17.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | s Item 2.03 by reference in its entirety. Item 5.02. Departure of Directors or Certain Officers; Election of Directo |
| 16.02.2024 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | the Exchange Act. ☐ Item 4.02. Non-Reliance on Previously Issued Financial Statements and Completed Interim R |
| 27.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | eport is incorporated herein by reference. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 05.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
Unternehmen & Branche
| Name | AEON Biopharma, Inc. |
|---|---|
| Ticker | AEON |
| CIK | 0001837607 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 00775E102 |
|---|---|
| ISIN | US00775E1029 |
| Typ | Common Stock |
| Marktkapitalisierung | 11,7 Mio. USD |
| Beta | 0,74 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -39,222,000 | -3.95 | 5,560,000 | ||
| 2025-09-30 | 10-Q | -4,538,000 | -0.39 | 8,734,000 | -19,872,000 | |
| 2025-06-30 | 10-Q | -6,642,000 | -0.60 | 11,662,000 | -15,852,000 | |
| 2025-03-31 | 10-Q | 9,095,000 | 2.28 | 13,799,000 | -11,323,000 | |
| 2024-12-31 | 10-K | 42,005,000 | 72.93 | 3,142,000 | ||
| 2024-09-30 | 10-Q | -6,171,000 | -11.24 | 4,004,000 | -32,090,000 | |
| 2024-06-30 | 10-Q | 164,112,000 | 304.00 | 5,734,000 | -27,947,000 | |
| 2024-03-31 | 10-Q | -118,018,000 | -227.87 | 3,032,000 | -198,381,000 | |
| 2023-12-31 | 10-K | -323,954,000 | -627.33 | 6,845,000 | -153,044,000 | |
| 2023-09-30 | 10-Q | -297,711,000 | -8.01 | 17,619,000 | -121,740,000 | |
| 2023-07-21 | 10-Q | -27,661,000 | -0.20 | |||
| 2023-07-21 | 10-K | -60,678,000 | -0.44 | |||
| 2023-06-30 | 10-Q | -15,379,000 | -0.11 | 21,785,493 | -11,461,184 | |
| 2023-03-31 | 10-Q | -17,639,000 | -0.13 | 21,616,160 | -7,317,951 | |
| 2022-12-31 | 10-K | -52,556,000 | -0.38 | 10,778,000 | -287,500,000 | |
| 2022-09-30 | 10-Q | -10,438,000 | -0.08 | 277,322,541 | -11,551,714 | |
| 2022-06-30 | 10-Q | 1,867,104 | 276,514,447 | -12,369,045 | ||
| 2022-03-31 | 10-Q | 2,773,393 | 276,647,301 | -14,156,462 | ||
| 2021-12-31 | 10-K | 8,200,831 | 276,949,530 | -16,929,855 | ||
| 2021-09-30 | 10-Q | 5,658,942 | 277,202,966 | -17,177,729 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.